Patricia Renee Beaston MD PhD
Diabetes, Lipid Metabolism
Medical Officer
Join to View Full Profile
10903 New Hampshire AvenueWO71Silver Spring, MD 20993
Dr. Beaston is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Patricia Beaston, MD, PhD, is based in Olney, MD, and specializes in Clinical Regulatory consulting since retiring from the FDA. She completed her fellowship in Endocrinology, Diabetes, and Metabolism at Geisinger Health System and her residency in Internal Medicine at Drexel University College of Medicine/Hahnemann University Hospital. She served as a Medical Officer at the US Food and Drug Administration from 2000 to 2024 and has experience in managing conditions such as diabetes mellitus, osteoporosis, thyroid and pituitary diseases, and the development of an artificial pancreas. Her clinical regulatory work includes drugs, devices and biologics.
Education & Training
Geisinger Health SystemFellowship, Endocrinology, Diabetes, and Metabolism, 1997 - 1999
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1995 - 1997
MCP-Hahnemann College of MedicineClass of 1994
Certifications & Licensure
MD State Medical License 2025 - 2026
PA State Medical License 1995 - 2026
NC State Medical License 1999 - 2001
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- 6 citationsInnovations in technology for the treatment of diabetes: clinical development of the artificial pancreas (an autonomous system).David C. Klonoff, Charles L. Zimliki, Lcdr Alan Stevens, Patricia Beaston, Arleen Pinkos
Journal of Diabetes Science and Technology. 2011-05-01
Press Mentions
FDA Panel Supports Islet Cell Treatment for Type 1 DiabetesApril 16th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
